BioCeuticals statement on recent news reports on Andrographis

First and foremost, we deeply empathise with anyone who has experienced an adverse reaction with any of our products. The safety and well-being of our consumers is our top priority, and we meet all of the stringent regulatory requirements set forth by the Therapeutic Goods Administration (TGA). We encourage anyone who experiences an adverse reaction to seek medical advice and report the specific issue to our BioCeuticals Naturopathic Advisory Team on 1300 650 455 or by email at [email protected]. 

BioCeuticals’ commitment to patient care requires products to be dispensed by a health care professional. This ensures that appropriate guidance on product suitability and dosage is provided to each consumer.

Adverse reactions can happen with any therapeutic product and we have a strict pharmacovigilance system in place to thoroughly investigate and address any reports we are informed of. Products containing Andrographis may cause allergic reactions including anaphylaxis in some people, and all our products have always included the required warnings labelled on the packaging. 

In July 2024, the TGA released a safety advisory relating to Andrographis and we voluntarily took the proactive step to include an additional front of pack warning label on all products in our portfolio containing Andrographis. Additionally, we also communicated with our pharmacy and health care customers to reiterate the prescribing guidance, including the anaphylaxis warnings, so they can provide their patients with advice regarding the safe use of these products.   

To understand more on Andrographis paniculate, you can also read more information from Complementary Medicines Australia (CMA) here.